The impact of the COVID-19 pandemic on the operations of clinical trials across the globe is grave. Pharma and clinical research companies are trying to mitigate the challenges. The operations in the clinical trial space have stalled due to the fear of cross-infection. The healthcare industry has a two-pronged strategy to mitigate the effects of the pandemic a) assessment of the current situation b) the optimal way forward.

This white paper explores and examines the paradigm shifts taking place in the clinical trial sphere and how organizations are accepting the technological interventions. This paper also reinforces the urgent need to enable virtual clinical trials to help organizations adapt to the current scenario.